Monitor for the appointment or shareholder nomination of a new audit committee financial expert within the next 180 days. Absent timely compliance, expect potential downgrades in liquidity and increased volatility. Consider exposure to micro-cap biotech governance risks.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 9 $0.5300entry
- T+1 · 8mo ago +68.11%α +68.30% · $0.8910
- T+5 · 8mo ago +67.55%α +68.90% · $0.8880
- T+20 · 7mo ago +118.87%α +121.67% · $1.16
- T+60 · 6mo ago +43.40%α +31.41% · $0.7600
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Longeveron Inc. filed an 8-K disclosing that board member and audit committee financial expert Richard Kender resigned due to his new role at Seres Therapeutics, causing the company to fall out of Nasdaq compliance. The company appointed Dr. Roger Hajjar to the audit committee but still lacks a financial expert, triggering a delisting notice with a plan to appoint or elect a qualified director within 180 days.
Key Facts
- Richard Kender resigned from the Board and Audit Committee effective March 3, 2026, due to his appointment as Executive Chairman and Interim CEO of Seres Therapeutics.
- His resignation caused Longeveron to no longer comply with Nasdaq Listing Rule 5605(c)(2)(A), which requires at least three independent audit committee members, one of whom must be a financial expert.
- The company appointed Dr. Roger Hajjar to the Audit Committee on March 4, 2026, restoring the three-member requirement but still lacking a financial expert.
- Longeveron has a 180-day cure period to appoint or elect a director who qualifies as both independent and an audit committee financial expert.
- Failure to regain compliance within 180 days could result in delisting from Nasdaq.
Financial Impact
High risk of delisting, which would reduce liquidity, limit institutional ownership, and increase cost of capital. No direct financial figures disclosed.
Risk Factors
- Risk of Nasdaq delisting if a financial expert is not appointed within 180 days
- Reduced investor base and liquidity if delisted
- Ongoing governance concerns due to weakened audit committee oversight
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-024839 |
| Document: 0001213900-26-024839-index-headers.html | 0001213900-26-024839 |
| Document: 0001213900-26-024839-index.html | 0001213900-26-024839 |
| Document: 0001213900-26-024839.txt | 0001213900-26-024839 |
Track record
22 reports on LGVN
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers